Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.59 |
| ▸ | MAOA | P21397 | 3/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12973292 | 1.00 | POLB (0.68) | POLBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL306161 | 0.90 | POLB (0.81) | POLBMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL14659297 | 0.90 | MAOB (0.76) | POLBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14659295 | 0.90 | MAOB (0.76) | POLBMEN1KMT2AALDH1A1MAPT | |
| Iodide SCHEMBL22235392 | 0.88 | POLB (0.78) | POLBMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL28404138 | 0.86 | POLB (0.52) | POLBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28404135 | 0.86 | POLB (0.52) | POLBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3559204 | 0.86 | NFE2L2 (0.67) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL3559206 | 0.86 | NFE2L2 (0.67) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL22624769 | 0.85 | PTPN1 (0.59) | POLBMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046731-B2 | Zinc-binder based EBNA1-specific compounds | HONG KONG BAPTIST UNIVERSITY (CN) | 2021-06-29 | — | — | US | disclosed |
| CN-111868022-A | EBNA1 specific compounds based on zinc binding agents | 香港浸会大学 | 2020-10-30 | — | — | CN | disclosed |
| CN-105524053-B | Tetrahydrobenzothiophene compounds | 广东东阳光药业有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-2772490-B1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-9284295-B2 | Tetrahydrobenzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2016-03-15 | — | — | US | disclosed |
| US-9062032-B2 | Aminoalkyl-substituted N-thienylbenzamide derivative | ASTELLAS PHARMA INC. (JP) | 2015-06-23 | — | — | US | disclosed |
| EP-2565190-B1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20140329802-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-11-06 | — | — | US | disclosed |
| EP-2772490-A1 | AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8729068-B2 | Tetrahydrobenzothiophene compound | ASTELLAS PHARMA INC. (JP) | 2014-05-20 | — | — | US | disclosed |
| EP-2565190-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130053369-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130029973-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329802-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | SLC34A2, SLC34A1, SLC10A2 | POLB 2011/4885MEN1 2848/4885KMT2A 1858/4885 |
| US-20130029973-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | SLC34A2, SLC10A2, SLC34A1 | POLB 2071/4885MEN1 2063/4885KMT2A 1940/4885 |
| US-20130053369-A1 | TETRAHYDROBENZOTHIOPHENE COMPOUND | SLC34A2, SLC34A1, SLC10A2 | POLB 2011/4885MEN1 2848/4885KMT2A 1858/4885 |
| US-20150031727-A1 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE | SLC34A2, SLC10A2, ALPI | POLB 1595/4885MEN1 3822/4885KMT2A 1493/4885 |
| US-11046731-B2 | Zinc-binder based EBNA1-specific compounds | ZC3HAV1, EBNA1BP2, ZC3HAV1L | POLB 1807/4885MEN1 753/4885KMT2A 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.